Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance

Take a look inside the London 2014 Congress


Then register to join us
in Barcelona!


Search Abstracts by author or title
(results will display both Free Papers & Poster)

Incidence of Nd:YAG capsulotomy of a hydrophobic glistening-free intraocular lens (MX60)

Poster Details

First Author: T.Tran FRANCE

Co Author(s):                        

Abstract Details


To evaluate the incidence of Nd:YAG capsulotomy over 3 years on a large series of eyes implanted with a hydrophobic intra-ocular lens (IOL) with 4% water content (MX60 IOL, Bausch + Lomb). The lens is designed with an aberration-free aspheric optic and a 360┬░posterior sharp square edge.


Retrospective study in a university-based single center.


Charts of 245 eyes of (149 patients) implanted with a hydrophobic acrylic IOL (MX60) from May 2011 to May 2013 were retrospectively reviewed. Following data were recorded: age at time of surgery, sex, surgical complications, associated ocular pathologies, date of Nd: YAG laser capsulotomy. All cataract surgeries were performed by a single surgeon. Only uneventful in-the -capsular bag implantations with a minimum of 24 months follow-up were included in the study. Time from IOL implantation to Nd: YAG laser capsulotomy was analyzed with Kaplan-Meier survival curves.


227 eyes of 143 patients fulfill the selection criteria: mean follow-up was 36 months (24 to 48 months), age ranged from 55 to 95 years, 67.7% were female, 31% reported associated ocular pathologies. 5 eyes of 227 (2.2%) had an Nd: YAG laser capsulotomy at 6, 9, 28, 28 and 41 months after implantation. Survival curves analysis will be available at the time of the presentation.


In this retrospective series of 227 eyes, with a mean follow-up of 3 years, the MX60 IOL demonstrated to be effective in preventing posterior capsule opacification, with a 2.2% Nd: YAG capsulotomy rate.

Financial Disclosure:

One or more of the authors research is funded, fully or partially, by a competing company

Back to Poster listing